{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T16:25:20Z","timestamp":1761582320763,"version":"3.40.5"},"reference-count":27,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,12,12]],"date-time":"2023-12-12T00:00:00Z","timestamp":1702339200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Microbiology, Immunology and Infection"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1016\/j.jmii.2023.12.004","type":"journal-article","created":{"date-parts":[[2023,12,14]],"date-time":"2023-12-14T22:36:42Z","timestamp":1702593402000},"page":"320-327","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Ribotypes and antimicrobial susceptibility profiles of clinical Clostridioides difficile isolates: A multicenter, laboratory-based surveillance in Taiwan, 2019\u20132021"],"prefix":"10.1016","volume":"57","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9391-1561","authenticated-orcid":false,"given":"Chin-Shiang","family":"Tsai","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7423-6783","authenticated-orcid":false,"given":"Po-Liang","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Min-Chi","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tai-Chin","family":"Hsieh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei-Ting","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jann-Tay","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wen-Chien","family":"Ko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jmii.2023.12.004_bib1","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1056\/NEJMra1403772","article-title":"Clostridium difficile infection","volume":"372","author":"Leffler","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jmii.2023.12.004_bib2","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1056\/NEJMoa1910215","article-title":"Trends in U.S. burden of Clostridioides difficile infection and outcomes","volume":"382","author":"Guh","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jmii.2023.12.004_bib3","article-title":"Comparison of trends in Clostridioides difficile infections in hospitalised patients during the first and second waves of the COVID-19 pandemic: a retrospective sentinel surveillance study","volume":"19","author":"Vendrik","year":"2022","journal-title":"Lancet Reg Health \u2013 Eur"},{"key":"10.1016\/j.jmii.2023.12.004_bib4","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.2147\/IDR.S162874","article-title":"Nationwide surveillance of ribotypes and antimicrobial susceptibilities of toxigenic Clostridium difficile isolates with an emphasis on reduced doxycycline and tigecycline susceptibilities among ribotype 078 lineage isolates in Taiwan","volume":"11","author":"Hung","year":"2018","journal-title":"Infect Drug Resist"},{"key":"10.1016\/j.jmii.2023.12.004_bib5","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.anaerobe.2018.10.011","article-title":"A systematic review of the use of rifaximin for Clostridium difficile infections","volume":"55","author":"Ng","year":"2019","journal-title":"Anaerobe"},{"key":"10.1016\/j.jmii.2023.12.004_bib6","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1099\/jmm.0.028571-0","article-title":"Rifaximin disc diffusion test for in\u00a0vitro susceptibility testing of Clostridium difficile","volume":"60","author":"Huhulescu","year":"2011","journal-title":"J Med Microbiol"},{"key":"10.1016\/j.jmii.2023.12.004_bib7","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1056\/NEJMoa0910812","article-title":"Fidaxomicin versus vancomycin for Clostridium difficile infection","volume":"364","author":"Louie","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jmii.2023.12.004_bib8","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/S1473-3099(11)70374-7","article-title":"Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a double-blind, non-inferiority, randomised controlled trial","volume":"12","author":"Cornely","year":"2012","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.jmii.2023.12.004_bib9","doi-asserted-by":"crossref","first-page":"3943","DOI":"10.1128\/AAC.00191-12","article-title":"Characterizations of clinical isolates of Clostridium difficile by toxin genotypes and by susceptibility to 12 antimicrobial agents, including fidaxomicin (OPT-80) and rifaximin: a multicenter study in Taiwan","volume":"56","author":"Liao","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jmii.2023.12.004_bib10","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1056\/NEJMoa051590","article-title":"An epidemic, toxin gene-variant strain of Clostridium difficile","volume":"353","author":"McDonald","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jmii.2023.12.004_bib11","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/S0140-6736(10)61266-4","article-title":"Clostridium difficile infection in Europe: a hospital-based survey","volume":"377","author":"Bauer","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.jmii.2023.12.004_bib12","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/2047-2994-2-21","article-title":"Epidemiology of Clostridium difficile infection in Asia","volume":"2","author":"Collins","year":"2013","journal-title":"Antimicrob Resist Infect Control"},{"key":"10.1016\/j.jmii.2023.12.004_bib13","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1080\/22221751.2019.1621670","article-title":"Clostridium difficile ribotype 017 \u2013 characterization, evolution and epidemiology of the dominant strain in Asia","volume":"8","author":"Imwattana","year":"2019","journal-title":"Emerg Microb Infect"},{"key":"10.1016\/j.jmii.2023.12.004_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.anaerobe.2019.03.007","article-title":"Clostridioides (Clostridium) difficile infection burden in Japan: a multicenter prospective study","volume":"60","author":"Kato","year":"2019","journal-title":"Anaerobe"},{"key":"10.1016\/j.jmii.2023.12.004_bib15","unstructured":"Clinical & Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing (M100Ed33), 33rd ed. https:\/\/clsi.org\/standards\/products\/microbiology\/documents\/m100\/(accessed 12 April 2023)."},{"key":"10.1016\/j.jmii.2023.12.004_bib16","unstructured":"Clinical and Laboratory Standards Institute. Methods for Antimicrobial Susceptibility Testing of Anaerobic Bacteria (M11), 9th ed. https:\/\/clsi.org\/standards\/products\/microbiology\/documents\/m11\/(accessed 12 April 2023)."},{"key":"10.1016\/j.jmii.2023.12.004_bib17","unstructured":"EUCAST: clinical breakpoints and dosing of antibiotics. https:\/\/www.eucast.org\/clinical_breakpoints (accessed 12 April 2023)."},{"key":"10.1016\/j.jmii.2023.12.004_bib18","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1128\/JCM.37.2.461-463.1999","article-title":"PCR targeted to the 16S-23S rRNA gene intergenic spacer region of Clostridium difficile and construction of a library consisting of 116 different PCR ribotypes","volume":"37","author":"Stubbs","year":"1999","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.jmii.2023.12.004_bib19","doi-asserted-by":"crossref","first-page":"4031","DOI":"10.1128\/JCM.41.9.4031-4037.2003","article-title":"Epidemiology and molecular characterization of Clostridium difficile strains from patients with diarrhea: low disease incidence and evidence of limited cross-infection in a Swedish teaching hospital","volume":"41","author":"Svenungsson","year":"2003","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.jmii.2023.12.004_bib20","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1111\/j.1574-6968.1999.tb13629.x","article-title":"Development of a new PCR-ribotyping method for Clostridium difficile based on ribosomal RNA gene sequencing","volume":"175","author":"Bidet","year":"1999","journal-title":"FEMS Microbiol Lett"},{"key":"10.1016\/j.jmii.2023.12.004_bib21","unstructured":"Clostridioides difficile ribotyping network (CDRN) service. GOV.UK. https:\/\/www.gov.uk\/government\/collections\/clostridium-difficile-ribotyping-network-cdrn-service (accessed 28 May 2023)."},{"key":"10.1016\/j.jmii.2023.12.004_bib22","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.anaerobe.2016.06.002","article-title":"Zoonotic potential of the Clostridium difficile RT078 family in Taiwan","volume":"41","author":"Tsai","year":"2016","journal-title":"Anaerobe"},{"key":"10.1016\/j.jmii.2023.12.004_bib23","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1016\/j.jmii.2022.05.002","article-title":"Hypervirulent Clostridioides difficile RT078 lineage isolates from the river: a potential reservoir for environmental transmission","volume":"55","author":"Tsai","year":"2022","journal-title":"J Microbiol Immunol Infect"},{"key":"10.1016\/j.jmii.2023.12.004_bib24","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.3201\/eid2806.212262","article-title":"Characterization of healthcare-associated and community-associated Clostridioides difficile Infections among adults, Canada, 2015-2019","volume":"28","author":"Du","year":"2022","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.jmii.2023.12.004_bib25","doi-asserted-by":"crossref","DOI":"10.2807\/1560-7917.ES.2022.27.49.2200244","article-title":"Sentinel surveillance and epidemiology of Clostridioides difficile in Denmark, 2016 to 2019","volume":"27","author":"Persson","year":"2022","journal-title":"Euro Surveill"},{"key":"10.1016\/j.jmii.2023.12.004_bib26","doi-asserted-by":"crossref","DOI":"10.1128\/spectrum.03582-22","article-title":"Spore-forming Clostridium (Clostridioides) difficile in wastewater treatment plants in western Australia","volume":"11","author":"Chisholm","year":"2023","journal-title":"Microbiol Spectr"},{"key":"10.1016\/j.jmii.2023.12.004_bib27","first-page":"2138","article-title":"Genome analysis of Clostridium difficile PCR ribotype 014 lineage in Australian pigs and humans reveals a diverse genetic repertoire and signatures of long-range interspecies transmission","volume":"7","author":"Knight","year":"2016","journal-title":"Front Microbiol"}],"container-title":["Journal of Microbiology, Immunology and Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1684118223002347?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1684118223002347?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,3,22]],"date-time":"2024-03-22T10:43:16Z","timestamp":1711104196000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1684118223002347"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":27,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["S1684118223002347"],"URL":"https:\/\/doi.org\/10.1016\/j.jmii.2023.12.004","relation":{},"ISSN":["1684-1182"],"issn-type":[{"type":"print","value":"1684-1182"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ribotypes and antimicrobial susceptibility profiles of clinical Clostridioides difficile isolates: A multicenter, laboratory-based surveillance in Taiwan, 2019\u20132021","name":"articletitle","label":"Article Title"},{"value":"Journal of Microbiology, Immunology and Infection","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jmii.2023.12.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC.","name":"copyright","label":"Copyright"}]}}